https://www.selleckchem.com/pr....oducts/Azacitidine(V
Background Patients with coronavirus disease 2019 (COVID-19) usually have fever and respiratory tract complaints; however, many report gastrointestinal (GI) symptoms. The frequency of GI symptoms ranges from 16% to 61%. Although COVID-19 morbidity and mortality are related to pulmonary disease, poor outcomes have been linked to GI symptoms. Therefore, this study aimed to determine the outcomes of COVID-19 patients who presented with GI symptoms. Methods We conducted a retrospective cohort study at Isra University Hospital in